hotspot -WSS

hotspot

author：entertainment 2025-10-01 14:20:39 - browse：731

LONDON — Seeking to build up its pharma business, the Japanese conglomerate Asahi Kasei is moving to buy Swedish biotech Calliditas Therapeutics in a nearly $1.1 billion cash deal, the companies said Tuesday.

The firm’s offer of $19.68 per share amounts to an 83% premium versus Calliditas’ closing price on a Swedish exchange Monday. The Calliditas board has unanimously recommended that shareholders accept the offer, the company said, adding that it “aims to realize the benefits of being part of a larger platform” by being acquired.

Calliditas has an approved drug on the U.S. market called Tarpeyo, which treats a kidney disease called IgA nephropathy. The condition has in recent years attracted interest from a number of pharma companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Flu, Covid vaccination rates decline, new survey data show

hotspot

WSS

Microbiome research is starting to find links to chronic diseases

Stop Congress from blocking public access to science

What we owe ALS patients — and why one company fell short

RSV injection headlines need to be accurate for good uptake

What will Novo Nordisk's VC do with its influx of cash?

Changes to biosimilar regulatory framework must prioritize patients

explore

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

As demand for Covid shots wanes, Moderna seeks its next success

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

How to save PrEP access — and even expand it

WHO recommends second malaria vaccine

Affirmative action in medical school literally saved lives

Senate HELP committee spars over health care workforce policies

How to save PrEP access — and even expand it

CRISPR base editing slashes cholesterol levels in monkeys

Alkermes shareholders re

Flu, Covid vaccination rates decline, new survey data show

entertainment

Ukraine and a new approach to mental health in war

Emergency workers more likely to restrain Black patients: study

Congress extends some pandemic preparedness programs

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Emergency workers more likely to restrain Black patients: study

CommonSpirit Health keeps growing, even as it loses money

hotspot

focus

hotspot

hotspot